Acute Lymphoblastic Leukemia

In an in vitro study which involved the use of a line of wild-type Ikaros-inducible IKZF1 mutant human precursor B cells (a model of BCR-ABL1+ precursor B cell acute lymphoblastic leukemia [pre-B ALL]… (full text at CIViC)

PMID 28190001 · Schjerven et al., 2017 · Open in CIViC

In this phase 1/2, open‐label, two‐part study, advanced leukemia patients with prior treatment failure (accelerated‐phase [AP, n = 79] chronic myeloid leukemia [CML], blast‐phase [BP, n = 64] CML, acu… (full text at CIViC)

PMID 26040495 · Gambacorti-Passerini et al., 2015 · Open in CIViC

SFPQ-ABL1fusion was identified in Ph-like ALL

PMID 31935290 · Harvey et al., 2020 · Open in CIViC

patients with Ph-like ALL had an inferior 5-year event-free survival compared with patients with non–Ph-like ALL (22.5% [95% CI, 14.9% to 29.3%; n = 155] v 49.3% [95% CI, 42.8% to 56.2%; n = 247], res… (full text at CIViC)

PMID 27870571 · Roberts et al., 2017 · Open in CIViC

In frame AGGF1:PDGFRb (exons 1-10 and exons 11-23) containing the PDGFRb tyrosine kinase domain, with no additional mutations, was observed in a 4 year old patient with T-ALL, found by RNAseq and conf… (full text at CIViC)

PMID 29284681 · Zabriskie et al., 2018 · Open in CIViC

A 4 yr old boy presented with a history of 1 week with fatigue, weakness, fever and vomiting. Physical examination showed prominent hepatosplenomegaly and white blood cell count of 622.8x109/L with … (full text at CIViC)

PMID 29284681 · Zabriskie et al., 2018 · Open in CIViC

Ba/F3 cells with AGGF1:PDGFRb showed IL3 independent growth. Patient derived cells and Ba/F3, both with AGGF1:PDGFRb, were treated with erlotinib, gefitinib, ibrutinib, and vandetanib. IC50 for inhibi… (full text at CIViC)

PMID 29284681 · Zabriskie et al., 2018 · Open in CIViC

Primary mononuclear cells from a 4 year old patient with AGGF1:PDGFRb were treated with PDGFRb inhibitors, which resulted in cell death. IC50 for reduction in cell viability were approximately Ponatin…

Prior to dasatinib treatment, one imatinib-resistant patient with acute lymphoblastic leukemia had the BCR-ABL1 fusion with no secondary variants in at least ten bacterial clones generated using perip… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

Prior to dasatinib treatment, one imatinib-resistant patient with acute lymphoblastic leukemia had the BCR-ABL1 fusion with the E255K secondary variant in 3/12 bacterial clones generated using periphe… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

In a retrospective study of 45 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABLfusion positive (Ph+) chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia (ALL) patients, a Ph+… (full text at CIViC)

PMID 17339191 · Soverini et al., 2007 · Open in CIViC

In an in vitro kinase study, the recombinant ABL1 H396P mutant kinase did not demonstrate resistance to bosutinib treatment at concentrations of 1μM and 10μM (activity %: 1 and 1) when compared to wil… (full text at CIViC)

PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC

In a retrospective study of 84 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABL1 fusion positive (Ph+) chronic myeloid leukemia (in accelerated-phase or with blast crisis) or Ph+ acut… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

In this open-label, phase II study, 36 patients with Ph-positive imatinib-resistant or intolerant ALL previously treated with standard induction or consolidation chemotherapy, or imatinib-resistant or… (full text at CIViC)

PMID 17496201 · Ottmann et al., 2007 · Open in CIViC

Bone marrow mononuclear cells (BM MNCs) were isolated from three acute lymphoblastic leukemia patients with the BCR-ABL1 T315I variant who were pretreated with various chemotherapeutics and dasatinib.… (full text at CIViC)

PMID 25686603 · Pemovska et al., 2015 · Open in CIViC

In a retrospective study of 45 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABL fusion positive (Ph+) chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia (ALL) patients, pati… (full text at CIViC)

PMID 17339191 · Soverini et al., 2007 · Open in CIViC

Prior to dasatinib treatment, one imatinib-resistant patient with acute lymphoblastic leukemia had the BCR-ABL1 fusion with Y253H and Y253H/Q252R variants in 9/10 and 1/10 clones, respectively. Clones… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

A 47-year-old man was diagnosed with pre-B-cell acute lymphoblastic leukemia. FISH and nested PCR revealed the patient had a t(4;22)(q12;11) translocation that created an in-frame BCR-PDGFRA fusion. T… (full text at CIViC)

PMID 12944919 · Trempat et al., 2003 · Open in CIViC

A preclinical study investigated BTK inhibitor ibrutinib as a potential inhibitor for patients with pre-BCR + B cell acute lymphoblastic leukemia (B-ALL). In validating the significance of BTK and BLK… (full text at CIViC)

PMID 28031181 · Kim et al., 2017 · Open in CIViC

A preclinical study investigated BTK inhibitor ibrutinib as a potential inhibitor for patients with pre-BCR + B cell acute lymphoblastic leukemia (B-ALL). In validating the significance of BTK and BLK… (full text at CIViC)

PMID 28031181 · Kim et al., 2017 · Open in CIViC

A somatic out-of-frame CD74intr::PDGFRB rearrangement joined CD74 exon 1 to PDGFRB exon 11 and retained 75 bp of CD74 intronic sequence containing a premature stop codon. Rather than producing a conve… (full text at CIViC)

PMID 36810896 · Sadras et al., 2023 · Open in CIViC

A 22-month-old patient with high-risk Philadelphia chromosome-like B-cell acute lymphoblastic leukemia harboring CD74intr::PDGFRB had 46.3% residual bone marrow blasts at the end of induction therapy.… (full text at CIViC)

PMID 36810896 · Sadras et al., 2023 · Open in CIViC

CDKN2A/B deletions were poor prognostic factors for both overall survival (OS) (HR = 2.15, 95% CI 1.82-2.54) and event-free survival (EFS)/disease-free survival (DFS)/relapse-free survival (RFS) (HR =… (full text at CIViC)

PMID 30592434 · Zhang et al., 2019 · Open in CIViC

A total of thirteen studies including 2857 patients were combined in a meta-analysis. Combined HRs suggested that CDKN2A/B deletions were poor prognostic factors for both overall survival (OS) (HR = 2… (full text at CIViC)

PMID 30592434 · Zhang et al., 2019 · Open in CIViC

Mullighan et al analyzed a cohort of 71 diagnosis-relapse cases and 270 acute leukaemia cases that did not relapse. The authors found that 18.3% of relapse cases had sequence or deletion mutations of … (full text at CIViC)

PMID 21390130 · Mullighan et al., 2011 · Open in CIViC

In vitro expression experiments of CRLF2 F232C in murine BaF3 cells and human UT7 cells show that this mutation leads to constitutive dimerization and cytokine-independent signaling. This leads to tra… (full text at CIViC)

PMID 20018760 · Yoda et al., 2010 · Open in CIViC

CRLF2 is overexpressed in 7% of B cell ALL. In KZF1-mutated, BCR-ABL1-negative ALL, also refers as “Ph-like ALL” , 50 % of these “Ph-like ALL” carry rearrangements of CRLF2 (CRLF2r). In particular, IG… (full text at CIViC)

PMID 22897847 · Roberts et al., 2012 · Open in CIViC

To investigate the therapeutic potential of JAK inhibitors in pediatric B-ALL, the authors examined the efficacy of rapamycin in murine xenograft models of 8 pediatric B-ALL cases. Five xenografts (I … (full text at CIViC)

PMID 22955920 · Maude et al., 2012 · Open in CIViC

Lack of association of CRLF2 V2del with any clinical value in acute lymphocytic leukemia.

PMID 29449437 · Sinclair et al., 2018 · Open in CIViC

In adult patients with early (n = 30), cortical (n = 30), mature (n = 3) or unknown (n = 8) T-cell acute lymphoblastic leukemia, those with mutations in DNMT3A (n=12) had shorter overall survival than… (full text at CIViC)

PMID 23341344 · Grossmann et al., 2013 · Open in CIViC

Ph- ALL (Philadelphia chromosome negative acute lymphoblastic leukemia) gene expression profiles cluster into two main groups, Ph like and non-Ph like ALL. Non-Ph like ALL have favorable outcomes whe… (full text at CIViC)

PMID 27019113 · Yasuda et al., 2016 · Open in CIViC

A screen for fusion genes in Ph- AYA-ALL (Philadelphia chromosome negative acute lymphoblastic leukemia in adolescents and young adults) was performed using RNA-seq from multiple cohorts of ALL patien… (full text at CIViC)

PMID 27019113 · Yasuda et al., 2016 · Open in CIViC

Integrated genomic analysis of was performed for 1,988 childhood and adult B-ALL cases. 106 cases (5.3%) showed DUX4 rearrangements, commonly with the IGH region. These cases were characterized by a u… (full text at CIViC)

PMID 30643249 · Gu et al., 2019 · Open in CIViC

In a study of 176 ALL patients, consisting of 136 B- and 40 T-lineage, multiplex nested RT-PCR was used to look for ETV6 fusions. One patient had ETV6::ABL2 fusion. Patient was a 17 year old with kary… (full text at CIViC)

PMID 22373549 · Zhou et al., 2012 · Open in CIViC

The patient derived MT-ALL cell line was established from a mature T-ALL in first relapse. Uncultured blasts had an immunophenotype of mature CD3+ TCRa/b+ T lymphocytes with a functional T-cell rece… (full text at CIViC)

PMID 12406085 · Griesinger et al., 2002 · Open in CIViC

Two family pedigrees (one family with three generations and a small 4 member family spanning two generations) are presented. Exome sequencing was performed with 8 individuals from the first family, an… (full text at CIViC)

PMID 25807284 · Noetzli et al., 2015 · Open in CIViC

The A687V EZH2-mutant SUP-B8 B-ALL cell line exhibited the greatest sensitivity to EZH2 inhibitor (GSK126) compared to 7 other EZH2 wild-type B-ALL cell lines by cell proliferation assay. The increase… (full text at CIViC)

PMID 25253781 · Ott et al., 2014 · Open in CIViC

In mouse models, constitutive NOTCH signaling contributes to the genesis of breast cancer, medulloblastoma, and T cell leukemia, whereas in human cancer its role is best exemplified by T cell acute ly… (full text at CIViC)

PMID 17646409 · O'Neil et al., 2007 · Open in CIViC

In a preclinical genomic and functional study of pediatric acute lymphoblastic leukemia (n = 81 paired diagnosis–relapse samples), recurrent RAS-pathway mutations involving NRAS (exons 2-3), KRAS (exo… (full text at CIViC)

PMID 24316979 · Wong et al., 2014 · Open in CIViC

A 25-year-old Caucasian male presented with a second relapse of B-ALL. RNA sequencing revealed FLT3 overexpression (also confirmed by IHC). The patient was treated with 22 days of sunitinib, permittin… (full text at CIViC)

PMID 27181063 · Griffith et al., 2016 · Open in CIViC

FOXP1-ABL1 fusion was identified in Ph-like ALL

PMID 31935290 · Harvey et al., 2020 · Open in CIViC

CRLF2 overexpression was examined in 90 adult B-ALL patients with demographic data that lacked characteristic rearrangements and identified overexpression in 15/90 (16.67%). Disease-free survival was … (full text at CIViC)

PMID 20018760 · Yoda et al., 2010 · Open in CIViC

To investigate the therapeutic potential of JAK inhibitors in Ph-like ALL, the authors examined the efficacy of ruxolitinib in murine xenograft models of 8 pediatric B-ALL cases. Six xenografts (I to … (full text at CIViC)

PMID 22955920 · Maude et al., 2012 · Open in CIViC

This study identifies DUX4 rearrangements, specifically IGH::DUX4 fusions, as diagnostic markers for a distinct molecular subtype of Philadelphia chromosome-negative (Ph−) B-lymphoblastic leukemia/lym… (full text at CIViC)

PMID 27019113 · Yasuda et al., 2016 · Open in CIViC